Skip to main content
47°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Autolus Therapeutics Plc ADR
(NQ:
AUTL
)
6.240
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,680
Open
6.240
Bid (Size)
5.950 (1)
Ask (Size)
6.230 (1)
Prev. Close
6.240
Today's Range
6.240 - 6.240
52wk Range
1.610 - 7.450
Shares Outstanding
52,346,231
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 20, 2024
Via
Benzinga
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
March 18, 2024
Via
Benzinga
Performance
YTD
-8.77%
-8.77%
1 Month
-1.42%
-1.42%
3 Month
-5.88%
-5.88%
6 Month
+168.97%
+168.97%
1 Year
+256.57%
+256.57%
More News
Read More
12 Health Care Stocks Moving In Friday's After-Market Session
March 15, 2024
Via
Benzinga
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
March 12, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Analyst Expectations for Autolus Therapeutics's Future
December 13, 2023
Via
Benzinga
Earnings Scheduled For March 14, 2024
March 14, 2024
Via
Benzinga
Autolus Therapeutics's Earnings Outlook
March 13, 2024
Via
Benzinga
Autolus Therapeutics PLC (NASDAQ: AUTL) Climbs to New 52-Week High
November 20, 2023
Via
Investor Brand Network
Autolus Therapeutics announces publication in Blood Cancer Journal
March 11, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
February 29, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in Nature Communications
February 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Announces Pricing of Underwritten Offering
February 08, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in ACS Chemical Biology
January 23, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
January 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments
January 12, 2024
Via
Talk Markets
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
January 10, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 27, 2023
Via
Benzinga
Autolus Therapeutics Announces Changes to its Board of Directors
December 22, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 28, 2023
Via
Benzinga
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
November 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 15, 2023
Via
Benzinga
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
November 15, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces participation in upcoming conferences
November 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.